Results 141 to 150 of about 195,243 (312)

CML [PDF]

open access: yesBone Marrow Transplantation, 1999
openaire   +2 more sources

Medical haematology: Repositioning haematology at the centre of medicine

open access: yesBritish Journal of Haematology, EarlyView.
The complementary domains of Medical Haematology and Haemato‐Oncology share a biological framework. The left panel depicts red cells, platelets, coagulation, thrombosis and innate immunity, while the right panel shows lymphoid and myeloid malignancies.
Cheng Hock Toh, Imelda Bates, Sue Pavord
wiley   +1 more source

New concepts for CML clonality [PDF]

open access: hybrid, 2013
Jamshid S. Khorashad   +2 more
openalex   +1 more source

Malignant craniopharyngiomas: Institutional experience and literature review

open access: yesBrain Pathology, EarlyView.
We report the second case of malignant craniopharyngioma with BAP1 and TP53 mutations. A literature review identified 44 cases of malignant craniopharyngiomas with a median overall survival of 6 months. Eighteen (41%) occurred in patients without any history of radiation, suggesting that mechanisms other than radiation have contributed to their ...
Thomas J. Auen   +10 more
wiley   +1 more source

Cytogenetic study in CML

open access: yesIndian Journal of Medical Research, 2012
Chronic myeloid leukaemia (CML) is a clonal stem cell disorder characterized by increased proliferation of myeloid lineage. CML is the commonest adult leukaemia in India and the annual incidence ranges from 0.8–2.2/100,000 population in males and 0.6–1.6/100,000 population in females in India1. The median age of diagnosis is 38-40 years.
openaire   +2 more sources

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

open access: yesCancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu   +7 more
wiley   +1 more source

Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies

open access: yesCancer Science, EarlyView.
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji   +2 more
wiley   +1 more source

Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms

open access: yesCancer Science, EarlyView.
In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley   +1 more source

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells [PDF]

open access: bronze, 2007
Heather G. Jørgensen   +4 more
openalex   +1 more source

Representativeness of the Natura 2000 network for preserving plant biodiversity in the European Union

open access: yesConservation Biology, EarlyView.
Abstract The Natura 2000 (N2K) network of protected areas is one of the main tools for area‐based conservation in the European Union (EU), yet its role in preserving plant biodiversity requires better understanding. We examined data kept in the European Vegetation Archive from over 1.2 million vegetation plots and obtained over 14.2 million plant ...
Michele Di Musciano   +41 more
wiley   +1 more source

Home - About - Disclaimer - Privacy